Question · asked by 1 review

Mycophenolate mofetil vs IV cyclophosphamide: Ovarian failure

It is very uncertain whether mycophenolate mofetil (MMF) changes ovarian failure compared with IV cyclophosphamide (CPA) (very low certainty).

What each review found

Current versions only
FindingEffectStudiesGRADE certainty
Mycophenolate mofetil (MMF) vs IV cyclophosphamide (CPA)
Ovarian failure · patients with induction therapy in lupus nephritis
It is very uncertain whether mycophenolate mofetil (MMF) changes ovarian failure compared with IV cyclophosphamide (CPA) (very low certainty).
Immunosuppressive treatment for proliferative lupus nephritis (2018) · Cochrane Headline outcomes only
RR 0.36 [0.06, 2.18]3 studies · 539 participantsVery low
MMF vs IV cyclophosphamide
Ovarian failure · Patients with induction therapy in lupus nephritis
MMF leads to lower ovarian failure compared with IV cyclophosphamide (high certainty).
Immunosuppressive treatment for proliferative lupus nephritis (2012) · Cochrane Headline outcomes onlyearlier version CD002922.PUB3, superseded
RR 0.15 [0.03, 0.8]2 studies · 498 participantsHigh

Findings are shown side by side, never pooled across reviews.

The reviews

ReviewSearched up toIncluded studiesAMSTAR 2
Immunosuppressive treatment for proliferative lupus nephritis
2018 · Cochrane Headline outcomes only
Not reportedlist not extracted yetNot assessed

Studies behind the findings

None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.

How reviews are matched to this question

Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.